Core Insights - Inovio Pharmaceuticals Inc reported a smaller fourth-quarter loss than expected, with a diluted loss of 26 cents per share, better than the analyst consensus of 38 cents and an improvement from a 65-cent loss a year earlier [2] - The company highlighted progress on its lead DNA medicine candidate, INO-3107, which has received FDA acceptance for its biologics license application, with a target action date of October 30 [3] Financial Performance - For the full year 2025, Inovio posted a net loss of $84.9 million, down from $107.3 million in 2024, while total operating expenses decreased to $86.9 million from $112.6 million [2] - The fourth-quarter results included a $21.2 million non-cash gain related to warrant liabilities, which can create volatility in reported income [3] Cash Position and Runway - The company ended 2025 with $58.5 million in cash, cash equivalents, and short-term investments, with resources expected to fund operations into the fourth quarter of 2026, including an estimated operational net cash burn of about $22 million in the first quarter of 2026 [4] Pipeline Developments - Inovio is advancing commercialization plans for INO-3107 and has announced a trial collaboration with Akeso to study INO-5412 in glioblastoma, providing additional pipeline catalysts for investors [4] Stock Performance - Inovio Pharmaceuticals shares were up 2.38% at $1.72 at the time of publication, indicating positive momentum in the stock [6]

Regulatory Approvals - The European Commission approved Johnson & Johnson's AKEEGA for metastatic hormone-sensitive prostate cancer (mHSPC) with BRCA1/2 mutations, marking its second approval in the EU [2] - Protalix BioTherapeutics received approval for a new dosing regimen of Elfabrio, allowing for 2 mg/kg every four weeks for adults with Fabry disease [5] - Incyte's Zynyz received a second indication for the first-line treatment of advanced squamous cell carcinoma of the anal canal [10] Clinical Trial Results - AKEEGA demonstrated a clinically meaningful delay in disease progression in the phase 3 AMPLITUDE trial, nearly halving the risk of progression or death compared to standard care [3] Product Details - AKEEGA was initially approved in April 2023 for metastatic castration-resistant prostate cancer (mCRPC) and is also approved in the U.S. for BRCA2-mutated metastatic castration-sensitive prostate cancer [4] - Elfabrio was originally approved in May 2023 with a dosing regimen of 1 mg/kg every two weeks [7] - Zynyz generated net product revenue of $66 million in 2025, a significant increase from $3.19 million in 2024 [12]

Hims shares are on pace for their best week on record as a new partnership with Novo fuels fresh optimism about the company’s future in weight-loss drugs https://t.co/WIEpbetHL3 ...

Core Viewpoint - China Medical System Holdings Limited (CMS) has received approval from the National Medical Products Administration (NMPA) for its new drug Desidustat Tablets, aimed at treating renal anaemia in non-dialysis adult Chronic Kidney Disease (CKD) patients [1][2]. Group 1: Product Approval and Market Impact - The approval of Desidustat Tablets enhances CMS's positioning in the nephrology sector and complements its existing product, Velphoro, which treats CKD hyperphosphatemia [2]. - CMS anticipates rapid clinical application of Desidustat Tablets through effective resource linkage and channel networks, aiming to provide differentiated treatment options for CKD patients in China [2]. Group 2: Clinical Efficacy and Unmet Needs - Desidustat Tablets function as a novel oral Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitor (HIF-PHI), promoting erythropoiesis by increasing endogenous erythropoietin and improving iron availability [3]. - Clinical trials in China have shown that Desidustat significantly increases haemoglobin levels compared to placebo, with long-term studies indicating it can maintain target haemoglobin levels safely [3]. - There is a significant unmet need for effective anaemia treatments in CKD patients, with over 120 million CKD patients in China and low treatment compliance rates among non-dialysis patients [4]. Group 3: Strategic Focus and Innovation - CMS follows an "innovation-driven" strategy, with a diverse product portfolio that includes 7 approved drugs and nearly 20 projects in clinical trials [6]. - The company aims to enhance its innovative pipeline with first-in-class and best-in-class products, focusing on clinical needs to deliver quality pharmaceutical solutions [6][8]. - CMS is committed to expanding its operations in specialty therapeutic fields, including cardiovascular, kidney, metabolic, gastroenterology, ophthalmology, and skin health, to strengthen its market position [9].

Core Insights - Kroger has launched the Zepbound® KwikPen at its pharmacies, enhancing access to Eli Lilly's weight-management medication for self-pay patients [1] - The introduction of the KwikPen allows eligible self-pay patients to benefit from manufacturer-sponsored savings programs for the first time at retail pharmacy locations [1] Group 1: Product Availability and Savings - Zepbound® KwikPen is now available at participating Kroger pharmacies, providing a convenient option for patients to obtain their medication [1] - Kroger honors Lilly's KwikPen Self-Pay Savings Card, which may help eligible patients reduce out-of-pocket costs [1] - This marks a significant development as it is the first time self-pay patients can access Lilly's savings program for this product at retail pharmacies [1] Group 2: Support Services for Patients - Patients filling GLP-1 prescriptions at Kroger have access to various services aimed at supporting adherence, education, and long-term health outcomes [1] - Services include referrals to dietitians, access to fresh foods, integrated care with The Little Clinic, virtual nutrition care, and personalized pharmacist counseling [1] - These services reflect Kroger's commitment to making healthcare more accessible and patient-centered [1]

Core Viewpoint - A securities fraud class action lawsuit has been filed against Soleno Therapeutics, Inc. for allegedly making materially false and misleading statements regarding its Phase 3 clinical trial for its product DCCR, which is intended for treating hyperphagia in individuals with Prader-Willi syndrome [2][4][5]. Company Overview - Soleno Therapeutics, Inc. is a pharmaceutical company based in Redwood City, California, focused on developing therapies for rare diseases. Its only commercial product is diazoxide choline extended-release tablets (DCCR) [4]. Lawsuit Details - The lawsuit was filed on behalf of investors who purchased Soleno common stock between March 26, 2025, and November 4, 2025. The case is registered in the United States District Court for the Northern District of California [2][7]. - Investors have until May 5, 2026, to file for lead plaintiff status [2][7]. Allegations - The complaint alleges that Soleno's executives misrepresented the safety of DCCR, downplaying significant safety concerns related to fluid retention in clinical trial participants [5]. - It is claimed that the administration of DCCR posed greater safety risks than disclosed, leading to lower commercial viability and potential adverse events post-launch [5]. - The lawsuit highlights that statements made by Soleno regarding its business and operations were materially false and misleading throughout the class period [5]. Stock Performance - Following the release of financial results on November 4, 2025, Soleno's stock price dropped over 26%, attributed to a report by Scorpion Capital that raised concerns about the DCCR launch trajectory and clinical trial issues [6][8]. Investor Actions - Investors are encouraged to contact Kessler Topaz Meltzer & Check, LLP for recovery options at no cost. They can seek to be appointed as lead plaintiff or remain an absent class member [3][9].

Core Insights - Ultragenyx Pharmaceutical (RARE) reported positive results from a late-stage study of its investigational AAV8 gene therapy, DTX301, for treating ornithine transcarbamylase (OTC) deficiency, demonstrating its potential for durable expression and activity following a single intravenous infusion [2] Study Results - The phase III Enh3ance study enrolled 37 patients, randomized to receive either DTX301 or placebo over a 36-week period, with patients in the placebo group crossing over to treatment after the controlled phase [3] - At week 36, DTX301-treated patients showed an 18% reduction in 24-hour plasma ammonia levels compared to placebo, achieving one of the primary endpoints, with average ammonia levels remaining within the normal range [4] - Among patients with elevated ammonia levels at baseline, 8 of 9 treated with DTX301 achieved normal ammonia levels, indicating a quick onset of effect as reductions were observed as early as week six [5] Treatment Benefits - DTX301-treated patients reduced the use of ammonia-scavenger drugs by 27% and increased protein intake by 13% by week 36, while maintaining normal ammonia levels [7][8] - Patient-reported outcomes indicated that 71% of treated patients reported being "much improved" in OTC symptoms compared to none in the placebo group, with 64% reporting moderate or substantial improvement [9] Safety Profile - DTX301 demonstrated an acceptable safety profile consistent with earlier phase I/II findings, with mild-to-moderate transient liver enzyme elevations being the most common treatment-emergent adverse events [10] - One serious adverse event of acute hepatitis occurred but resolved with steroid therapy, and no adverse events related to thrombotic microangiopathy or malignancies were reported [10] Future Steps - Ultragenyx is continuing the phase III Enh3ance study to evaluate a second primary endpoint focused on reducing overall treatment burden, with data expected in the first half of 2027 [11][13]

Core Viewpoint - 60 Degrees Pharmaceuticals Inc. experienced significant stock volatility, with a notable decline following a substantial increase due to positive trial results for its babesiosis treatment [1][2]. Group 1: Stock Performance - Shares of 60 Degrees Pharmaceuticals fell by 9.6%, closing at $2.91, after a previous surge of nearly 48% due to successful trial results [1]. - During premarket trading, shares were down 7.90% at $2.68 [6]. Group 2: Clinical Trial Results - The company's trial for babesiosis demonstrated a nearly 100% cure rate in immunosuppressed patients when tafenoquine was included in their treatment regimen [2]. - Tafenoquine, marketed as ARAKODA, is currently approved for malaria prophylaxis but is not yet FDA-approved for treating babesiosis [3]. Group 3: Partnerships and Market Position - In January, the company partnered with Runway Health to enhance access to ARAKODA through a telehealth platform for travelers [4]. - Analyst consensus indicates a Buy rating for the stock, with an average price target of $17.60, despite current weak momentum [5].

Financial Data and Key Metrics Changes - The company ended 2025 with cash totaling $7.6 million, an increase from $3.7 million as of December 31, 2024 [12] - The net loss for Q4 2025 was $1.6 million, or $0.73 per diluted share, compared to a net loss of $2.8 million, or $3.29 per diluted share for Q4 2024 [16] - For the full year 2025, the net loss was $8 million, or $5.32 per diluted share, down from a net loss of $14.1 million, or $17.45 per share in 2024 [16] Business Line Data and Key Metrics Changes - Research and development expenses for Q4 2025 were $0.3 million, down from $0.8 million in Q4 2024, primarily due to decreased manufacturing and consulting costs [13] - For the full year 2025, R&D expenses totaled $1.8 million, a significant decrease from $5.4 million in 2024, attributed to lower manufacturing and consulting costs [14] - General and administrative expenses for Q4 2025 were $1.3 million, down from $2 million in Q4 2024, mainly due to reduced compensation-related costs and professional fees [14] Market Data and Key Metrics Changes - The company presented at IDWeek in Atlanta, highlighting the potential of ibezapolstat and its microbiome-sparing properties, which could position it favorably in the market [4][5] - The FDA's recent announcement regarding a one-trial requirement for registration could significantly impact the company's clinical development programs and market entry strategy [10] Company Strategy and Development Direction - The company is launching a new clinical trial program for ibezapolstat in patients with recurrent CDI, aiming to shift treatment paradigms from two agents to one [7][19] - The company is pursuing funding opportunities for its phase 3 clinical trial programs and exploring alternative financial pathways [11] - The focus on U.S.-based manufacturing aligns with government interests in public-private partnerships, potentially enhancing funding opportunities [41] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in navigating the macroeconomic challenges and emphasized the competitive profile of ibezapolstat [12] - The potential for ibezapolstat to be the first agent to demonstrate clinical success in both treating and preventing recurrent CDI was highlighted as a significant opportunity [19] - The company is optimistic about the implications of the FDA's new guidance on clinical trial requirements for its development programs [10] Other Important Information - The company received a new patent for its Pol IIIC inhibitors, extending protection to December 2039 [10] - The clinical program for ibezapolstat has received fast track designations from the FDA, enhancing its development prospects [11] Q&A Session Summary Question: What is the primary endpoint for the recurrent CDI trial and its cost? - The primary endpoint is prevention of recurrence, with an evaluation period of eight weeks and a trial cost estimated between $4 million and $5 million [22][32] Question: When will the pilot study start and conclude? - Enrollment for the pilot study is expected to begin in the second half of 2026, with full enrollment anticipated to take 12-15 months [33] Question: How many patients will be needed for the phase 3 trial? - The current projection for the phase 3 trial in recurrent CDI is between 360 and 400 patients, depending on data from the open-label trial [37] Question: Is U.S.-based manufacturing a focus for the company? - Yes, the company is engaging with government agencies regarding U.S.-based manufacturing, which is seen as beneficial for securing funding [41]

CF PharmTech, Inc. 長風藥業股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2652） 自願公告 NMPA受理ICF001的IND申請 本公告乃由長風藥業股份有限公司（「本公司」，連同其附屬公司統稱「本集團」）自 願作出，以知會股東及潛在投資者有關本集團之最新研發進展。 引言 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容而產生或因依 賴該等內容而引致的任何損失承擔任何責任。 本公司董事（「董事」）會（「董事會」）欣然宣佈，本公司自主研發的吸入粉霧劑候 選藥物ICF001（「產品」）之新藥臨床試驗（「IND」）申請（「該申請」）已獲中華人民 共和國國家藥品監督管理局（「NMPA」）受理。茲公告相關資訊如下： 產品名稱 : ICF001（吸入粉霧劑） 受理號 : CXHL2600306/CXHL2600307/CXHL2600308/ CXHL2600309/CXHL2600310/CXHL2600311 申請人 : 長風蘇粵藥業（廣州）有限公司 （本公司之附屬公司 ...